Strong market position as the world's largest store-brand consumer health care and over the counter (OTC) company with a substantial position in infant nutrition. Good geographic diversity, comprehensive range of products and diverse customer and distribution channels. Favorable trend of transfer of prescription drugs to non-prescription OTC status helps drive volume growth. Despite a niche position in the specialty generic segment the company is experiencing generic price erosion in its base generics business. Uncertain strategic direction due to management turnover and the influence of an activist shareholder. The ongoing strategic review could result in the divestiture of the generic business. Adjusted leverage expected to decline to the 3x area by the end of 2017, from 4.8x in 2016 aided by
